Skip to content
10-Q

Quarterly Report

Applied Therapeutics, Inc.

0000950170-25-070557

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 141.58M sh
Shares Diluted Q1 2025 · Mar 31, 2025 144.79M sh
Shares Diluted Q1 2025 · Sep 30, 2024 125.32M sh
Shares Diluted Q1 2025 · Mar 31, 2024 125.32M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$28.64M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$18.91M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $50.76M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $79.4M
Stockholders Equity Q1 2025 · Mar 31, 2025 $36.67M
Stockholders Equity Q1 2025 · Dec 31, 2024 $57.01M
Stockholders Equity Q1 2025 · Mar 31, 2024 $67.29M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$17.15M
Current Liabilities Q1 2025 · Mar 31, 2025 $17.97M
Current Liabilities Q1 2025 · Dec 31, 2024 $27.3M
Total Liabilities Q1 2025 · Mar 31, 2025 $20.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $29.69M
Current Assets Q1 2025 · Mar 31, 2025 $53.97M
Current Assets Q1 2025 · Dec 31, 2024 $83.65M
Total Assets Q1 2025 · Mar 31, 2025 $56.91M
Total Assets Q1 2025 · Dec 31, 2024 $86.69M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.15
Eps Diluted Q1 2025 · Sep 30, 2024 −$0.67
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.67
Eps Basic Q1 2025 · Mar 31, 2025 −$0.15
Eps Basic Q1 2025 · Sep 30, 2024 −$0.67
Eps Basic Q1 2025 · Mar 31, 2024 −$0.67
Sga Expense Q1 2025 · Mar 31, 2025 $17.69M
Sga Expense Q1 2025 · Sep 30, 2024 $9.07M
Rd Expense Q1 2025 · Mar 31, 2025 $7.84M
Rd Expense Q1 2025 · Sep 30, 2024 $12.22M
Net Income Q1 2025 · Mar 31, 2025 −$21.83M
Net Income Q1 2025 · Sep 30, 2024 −$83.94M
Net Income Q1 2025 · Mar 31, 2024 −$83.94M
Operating Income Q1 2025 · Mar 31, 2025 −$25.53M
Operating Income Q1 2025 · Sep 30, 2024 −$21.09M
Revenue Q1 2025 · Mar 31, 2025 $0
Revenue Q1 2025 · Sep 30, 2024 $190K